Setterwalls has advised Qlife Holding in connection with rights issue

Setterwalls has advised Qlife Holding in connection with a rights issue of units, consisting of shares and warrants.

Qlife Holding develops and markets an innovative medical technology platform, with the goal of giving people access to clinical biomarker data when testing at home. The company’s products will be able to test for a variety of biomarkers and through more frequent and accessible testing, users will be able to monitor lifestyle markers or markers for chronic disease states and gain increased insight into their health, and consequent adaptation of treatment and lifestyle.

Through the rights issue, Qlife Holding receives initial issue proceeds of approximately SEK 53 million before issue costs. In addition, Qlife Holding may receive additional issue proceeds of not more than approximately SEK 76 million before issue costs, upon full exercise of all warrants that are issued in the rights issue.